Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause

References

• Barrett-Connor E, Laughlin GA. Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials. Semin Reprod Med. 2009;27(3):275–282.
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902.
   PubMed Web of Science ®Google Scholar
• The NAMS. 2017 hormone therapy position statement advisory panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Practice bulletin no. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–216.
   PubMed Web of Science ®Google Scholar
• Erekson EA, Li FY, Martin DK, et al. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders. Menopause. 2016;23(4):368–375.
   PubMed Web of Science ®Google Scholar
• Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133–2142.
   PubMed Web of Science ®Google Scholar
• Kingsberg S, Krychman M, Graham S, et al. The Women’s EMPOWER Survey: identifying women’s perceptions on vulvar and vaginal atrophy (VVA) and its treatment. J Sex Med. 2017;14(3):413–424.
   PubMed Web of Science ®Google Scholar
• Simon JA, Kokot-Kierepa M, Goldstein J, et al. Vaginal health in the United States: results from the vaginal health: insights, views & attitudes survey. Menopause. 2013;20(10):1043–1048.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA)–results from an international survey. Climacteric. 2012;15(1):36–44.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Mattsson LA, Lachowsky M, et al. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas. 2013;75(4):373–379.
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Portman D, Lefebvre P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2014;22(3):260–266.
   Web of Science ®Google Scholar
• Nappi RE, Palacios S, Bruyniks N, et al. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019;26(5):485–491.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, et al. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. 2013;10(9):2232–2241.
   PubMed Web of Science ®Google Scholar
• Jannini EA, Nappi RE. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev. 2018;6(3):384–395.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197.
   PubMed Web of Science ®Google Scholar
• Palma F, Xholli A, Cagnacci A, as the writing group of the Agata study. The most bothersome symptom of vaginal atrophy: evidence from the observational AGATA study. Maturitas. 2018;108:18–23.
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study Cohort. Menopause. 2014;21:924–932.
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539.
   PubMed Web of Science ®Google Scholar
• Krychman M, Graham S, Bernick B, et al. The Women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425–433.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–238.
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. 2014;21(9):911–916.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20.
   PubMed Web of Science ®Google Scholar
• Minkin MJ, Maamari R, Reiter S. Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health. 2013;5:133–139.
   PubMedGoogle Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–3253.
   PubMed Web of Science ®Google Scholar
• Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–3263.
   PubMed Web of Science ®Google Scholar
• Archer DF, Carr BR, Pinkerton JV, et al. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause. 2015;22(7):786–796.
   PubMed Web of Science ®Google Scholar
• Osphena® [(ospemifene) tablets, for oral use] Prescribing Information. Florham Park, NJ: Shionogi Inc; 2019 Jan.
   Google Scholar
• European Medicines Agency. Senshio. 2015 [cited 2015 Apr]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002780/smops/Positive/human_smop_000759.jsp&mid=WC0b01ac058001%E2%80%A6
   Google Scholar
• Unkila M, Kari S, Yatkin E, et al. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013;138:107–115.
   PubMed Web of Science ®Google Scholar
• Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141(2):809–820.
   PubMed Web of Science ®Google Scholar
• Kangas L, Harkonen P, Vaananen K, et al. Effects of the selective estrogen receptor modulator ospemifene on bone in rats. Horm Metab Res. 2014;46(1):27–35.
   PubMed Web of Science ®Google Scholar
• Kangas L, Harkonen P, Vaananen K, et al. Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats. Horm Metab Res. 2014;46(5):328–332.
   PubMed Web of Science ®Google Scholar
• Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77(4–5):271–279.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–486.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623–630.
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014;78(2):91–98.
   PubMed Web of Science ®Google Scholar
• Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randamized, double-blind placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.
   PubMed Web of Science ®Google Scholar
• Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012;19(1):96–103.
   PubMed Web of Science ®Google Scholar
• Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013;78(12–13):1273–1280.
   PubMed Web of Science ®Google Scholar
• Eigeliene N, Kangas L, Hellmer C, et al. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016;23(7):719–730.
   PubMed Web of Science ®Google Scholar
• Simon J, Portman D, Mabey RG Jr. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014;77(3):274–281.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–427.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182.
   PubMed Web of Science ®Google Scholar
• Kagan R, Portman D, Archer DF, et al. Responder analysis of ospemifene treatment for vulvar and vaginal atrophy in postmenopausal women in phase 3 randomized, placebo-controlled in trials Paper presented at: North American Menopause Society 25th Annual Meeting; 2014; Washington, DC, United States.
   Google Scholar
• Bruyniks N, Nappi RE, Castelo-Branco C, et al. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. 2016;19(1):60–65.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18(2):233–240.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019;121:86–92.
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Koltun WD, et al. Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med. 2014;11(4):1033–1041.
   PubMed Web of Science ®Google Scholar
• Goldstein SW, Winter AG, Goldstein I. Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study. Sex Med. 2018;6(2):154–161.
   PubMed Web of Science ®Google Scholar
• Murina F, Di Francesco S, Oneda S. Vulvar vestibular effects of ospemifene: a pilot study. Gynecol Endocrinol. 2018;34(7):631–635.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Simon JA, Kaunitz A, et al. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices. Menopause. 2019;26(9):994-1001.
   Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Martelli V, et al. Effects of ospemifene on vaginal epithelium of post-menopausal women. Gynecol Endocrinol. 2017;33(12):946–950.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Baldassarre M, Gava G, et al. Structure of epithelial and stromal compartments of vulvar and vaginal tissue from women with vulvo-vaginal atrophy taking ospemifene. J Sex Med. 2018;15(12):1776–1784.
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–232.
   PubMed Web of Science ®Google Scholar
• De Rosa N, Lavitola G, Giampaolino P, et al. Impact of Ospemifene on quality of life and sexual function in young survivors of cervical cancer: a prospective study. Biomed Res Int. 2017;2017:7513610.
   PubMed Web of Science ®Google Scholar
• Kubota R, Matsumoto S, Wajima T. Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors. Int J Clin Pharmacol Ther. 2017;55(4):339–347.
   PubMed Web of Science ®Google Scholar
• Bondi C, Ferrero S, Scala C, et al. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. Expert Opin Drug Metab Toxicol. 2016;12(10):1233–1246.
   PubMed Web of Science ®Google Scholar
• Uusitalo J, Turpeinen M, Tolonen A, et al. Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species. Drug Metab Pers Ther. 2016;31(1):35–40.
   PubMedGoogle Scholar
• Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health. 2012;21(2):161–169.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Archer DF, Pollycove R, et al. Ospemifene’s effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. Menopause. 2016;23(9):957–964.
   PubMed Web of Science ®Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt). 2018;27(1):14–23.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93–100.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause. 2015;22(1):36–43.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (FDA). Draft guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms–recommendations for clinical evaluation. 2003 Jan [cited 2018 Dec 21]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/informationbyDrugClass/UCM135338.pdf
   Google Scholar
• Goldstein SR. Postmenopausal dyspareunia: has the food and drug administration really helped? Menopause. 2013;20(6):596–597.
   PubMed Web of Science ®Google Scholar
• Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99(2):338–342.
   PubMed Web of Science ®Google Scholar
• De Villiers TJ. Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. Climacteric. 2009;12(Suppl 1):108–111.
   PubMed Web of Science ®Google Scholar
• Archer DF, Altomare C, Jiang W, et al. Ospemifene’s effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause. 2017;24(10):1167–1174.
   PubMed Web of Science ®Google Scholar
• Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol. 2004;18(3):152–158.
   PubMed Web of Science ®Google Scholar
• Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24(4):314–318.
   PubMed Web of Science ®Google Scholar
• Tucker KM, Godha K, Mirkin S, et al. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. Menopause. 2018;25(7):762–766.
   PubMed Web of Science ®Google Scholar
• Traish AM, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;6(4):558–571.
   PubMed Web of Science ®Google Scholar
• Hodgins MB, Spike RC, Mackie RM, et al. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol. 1998;105(2):216–222.
   PubMedGoogle Scholar
• Wang XN, Simmons HA, Salatto CT, et al. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause. 2006;13(4):609–620.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, D’Oria O, Aleksa N, et al. Usefulness of Ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery. Gynecol Endocrinol. 2019;35(2):155–159.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Sciuga V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–669.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol. 2017;33(12):942–945.
   PubMed Web of Science ®Google Scholar